IPR decision: Feb 10, 2020
|
AIA Review #
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent
|
Respondent
|
FINAL WRITTEN DECISION
|
|
IPR2018-01494
|
08/02/2018
|
02/15/2019
|
Neptune Generics LLC
|
8,921,348
|
Corcept Therapeutics Inc.
|
Claims 1-7 are patentable
|
US 8,921,348 (Corcept Therapeutics, Inc.; Exp: 08/27/2028) – listed in OB
1. A method for optimizing levels of mifepristone in a patient suffering from a disorder amenable to treatment by mifepristone, the method comprising: treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.
Leave a Reply